Candel Therapeutics, Inc. CADL Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$38.18M+30.8% | -$55.18M-45.4% | -$37.94M-102% | -$18.79M+50.2% | ||
| $808K-9.8% | $896K+1.9% | $879K+13.0% | $778K+235% | ||
| $3.82M-28.1% | $5.31M+71.9% | $3.09M+34.0% | $2.31M— | ||
| —— | $0+100% | -$79K— | —— | ||
| —— | -$185K— | —— | —— | ||
| —— | $757K— | —— | $1.27M— | ||
| —— | -$234K+53.5% | -$503K— | —— | ||
| $178K— | —— | -$192K-387% | $67K+154% | ||
| -$509K+0.8% | -$513K-10.6% | -$464K0.0% | -$464K— | ||
| -$38.31M-41.8% | -$27.02M+21.1% | -$34.24M-9.0% | -$31.42M-41.4% | ||
| $587K+3,569% | $16K-96.5% | $457K-64.8% | $1.3M-29.3% | ||
| $27K— | —— | —— | —— | ||
| -$560K-3,400% | -$16K+94.3% | -$280K+78.4% | -$1.3M+29.3% | ||
| —— | —— | —— | $64K— | ||
| $59.47M-36.9% | $94.28M+78,017% | -$121K-101% | $19.97M-72.2% | ||
| $17.23M-74.4% | $67.24M+294% | -$34.65M-172% | -$12.74M— | ||
| $1.28M-28.7% | $1.8M-16.4% | $2.15M+86.5% | $1.15M— | ||
| —— | —— | —— | $183K+531% | ||
| $360K+33.3% | $270K-16.4% | $323K+11.0% | $291K— | ||
| $808K-9.8% | $896K+1.9% | $879K— | —— | ||
| -$509K+0.8% | -$513K-10.6% | -$464K0.0% | -$464K— | ||
| $24K+145% | -$53K-146% | $116K— | —— | ||
| —— | -$234K+53.5% | -$503K— | —— | ||
| $138K+16.0% | $119K+15.5% | $103K+15.7% | $89K+17.1% | ||
| $321K+17.2% | $274K+14.2% | $240K+14.8% | $209K— | ||
| $47.95M— | —— | —— | —— | ||
| -$11.73M-28.0% | -$9.17M— | —— | —— | ||
| $135K— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| $93K— | —— | —— | —— | ||
| —— | $20.8M— | —— | -$16.37M— | ||
| $178K— | —— | -$192K-387% | $67K+154% | ||
| -$509K+0.8% | -$513K-10.6% | -$464K0.0% | -$464K— | ||
| $2.08M— | —— | —— | —— | ||
| -$38.9M-43.9% | -$27.04M+22.1% | -$34.7M-6.1% | -$32.72M-36.0% | ||
| -$38.9M-43.9% | -$27.04M+22.1% | -$34.7M-6.1% | -$32.72M-36.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Candel Therapeutics, Inc. generate?
- Candel Therapeutics, Inc. (CADL) generated -$47.7M in operating cash flow over the trailing twelve months.
- What is Candel Therapeutics, Inc.'s free cash flow?
- After $1.3M of capital expenditures, Candel Therapeutics, Inc.'s free cash flow was -$49.0M over the trailing twelve months, down 80.0% year over year.
- Where does Candel Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Candel Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
